Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind active-controlled study of XC2309 tablets for reflux esophagitis
CTR20261323Phase 3Active
- Sponsor
- Zhejiang Medicine Co., Ltd.
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of XC2309, lansoprazole in erosive esophagitis (EE), sponsored by Zhejiang Medicine Co., Ltd.. Started Apr 2026; status: active.
02
Drugs
XC2309lansoprazole
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on CTR20261323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261323.